Selfie fingerprint’ scam is ‘real,’ some AI experts warn — others say it’s bunk: ‘Stuff out of spy novels’

WIRED reported Meta embedded unreleased “NameTag” facial recognition code in the Meta AI app used with its smart glasses. One day later, Meta removed most NameTag traces from the latest update but did not explain why or whether it will return, according to WIRED and Meta VP Andy Stone. Meta also faces a class action alleging Meta Pixel unlawfully collects sensitive healthcare data.

Rubrik (NYSE: RBRK) launched Rubrik Annapurna, an AI-ready unstructured data layer for enterprise Data Intelligence platforms. It scans and catalogs unstructured files in place across NAS and S3, then publishes a queryable lakehouse catalog so users pull only needed subsets, aiming to cut duplication and ETL overhead. Rubrik says pipeline costs scale with consumption and governance/access controls are preserved.

AeroVironment (NASDAQ: AVAV) announced at Eurosatory 2026 the launch of TOM 50 RE, a backpackable uncrewed ground vehicle developed by its subsidiary Telerob. The company says it weighs under 10 kg, offers up to five hours of endurance, supports up to 5 kg payloads, and includes SLAM mapping, 360-degree IR-capable cameras, and secure IP-mesh communications for reconnaissance and EOD.

Poolbeg Pharma, a London startup, said it will trial its oral drug POLB 001 at six NHS hospitals to prevent cytokine release syndrome (CRS) in patients receiving blood cancer immunotherapy. The trial will enroll 30 people treated with Johnson & Johnson’s teclistamab (Tecvayli), led by the University of Manchester and Christie NHS Foundation Trust. Poolbeg expects interim data by end of summer; it estimates a $10bn market potential at $20,000 per treatment.

Amgen said at the American Diabetes Association 86th Scientific Sessions (June 7, 2026) that Phase 3 VESALIUS-CV subgroup data for Repatha in 6,002 high-risk diabetes patients reduced a composite endpoint (CHD death, MI, ischemic stroke) by 29% vs placebo and reduced a second composite including ischemia-driven revascularization by 21%. Separately, Goldman Sachs cut its AMGN price target to $389 from $425 while keeping a Buy rating, citing an IRS audit dispute disclosed in Q1.

Meta removed a facial recognition feature (“NameTag”) from the Ray-Ban smart glasses app in June 2026, according to the article. The feature in Meta AI could identify people and pull their Instagram/Facebook profiles without consent or notification. The change followed pressure from 70+ civil rights and privacy groups, which cited risks of street-level identification and surveillance. Meta made no public announcement.